In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.
Men with Medicaid are more likely to present with metastatic prostate cancer than men presenting with prostate cancer who have private insurance, according to a new study. There are racial disparities in terms of prostate cancer outcomes among those privately insured, but not among Medicaid recipients.
A large proportion of patients who underwent radical nephrectomy for kidney tumors were able to recover to their preoperative renal function, according to the results of a recent study.
An analysis of treatment patterns found that patients with advanced urinary tract cancer who are eligible for cisplatin-based chemotherapy fare better when they do receive such regimens than when they do not, highlighting the importance of following published treatment criteria.
Combination treatment with a novel CXCR4 inhibitor and axitinib resulted in an encouraging overall response rate and disease control rate in patients with clear cell renal cell carcinoma, according to the results from phase I of a phase I/II trial.
In this interview we discuss the STOPCaP trial, a meta-analysis that looked at optimal systemic therapy options for men with metastatic hormone-sensitive prostate cancer.
Patients with upper tract urothelial carcinoma who do not undergo definitive therapy have poorer outcomes than those who do, according to a new study.
Cabozantinib reduced the risk for disease progression or death by 52% compared with sunitinib in patients with previously untreated advanced renal cell carcinoma, according to updated results from the CABOSUN trial.
Treatment with pazopanib 600 mg had no benefit over placebo for patients who had undergone nephrectomy for localized or locally advanced renal cell carcinoma.
This video highlights potentially practice-changing studies on genitourinary cancers presented at the 2017 ASTRO Annual Meeting.